Lowest Price Guaranteed
Pages
317
Last Updated
July 2026
View Count
18633
Earlier, customers from North America demonstrated a preference for service providers within the US to outsource their ADME requirements; however, clients are now more willing to work across borders. Despite growing activity in other upcoming regions, I believe that the major proportion of activity in this field is still restricted to within North America, followed by Asia-Pacific and Europe.
-- Chief Scientific Officer, a US-based small-sized CRO
The global in vitro ADME toxicology testing market, valued at USD 4.5 billion in 2025, is projected to reach USD 5.2 billion in 2026 and USD 6.0 billion by 2030, with a 3.9% CAGR during the forecast period 2026 to 2030.
ADME toxicology test has been designed to study the absorption, distribution, metabolism, and excretion speed of drugs from the body. The assay has been extensively used by pharmaceutical companies during the drug discovery and testing process prior to shifting to in-vivo testing.
To learn more about this report, request a free sample copy
In recent years, the demand for therapeutic drugs has increased owing to the growing prevalence of chronic diseases. It is a well-known fact that the development of new drugs is highly demanding in terms of intense research, time, and investment. The overall success of therapeutic drugs in preclinical and clinical studies depends on the identification of biological targets and active compounds with higher therapeutic potential during an early stage. It is worth noting here that the overall investment in R&D initiatives by pharmaceutical companies has increased from nearly USD 128 billion in 2008 to USD 165 billion in 2018. Despite a keen identification process and huge investment, only a small fraction of therapeutic molecules discovered at an early stage are able to qualify for preclinical evaluation. As per the study conducted on terminated drug development programs, the low success rate of drugs in clinical trials was primarily attributed to problems associated with pharmacokinetic profiles and ADME (absorption, distribution, metabolism, and excretion). As a result, the high failure rate creates pressure on pharmaceutical companies for not fulfilling the ongoing demand for drugs.
To avoid drug failure at a late stage, ADME toxicology testing has now been mandated during the drug development process. ADME toxicology studies are crucial to determine the safety and efficacy of the drug candidates. Several technological approaches, such as in-silico techniques (a computer-based testing method), help in faster detection of absorption, distribution, metabolism, and excretion. Currently, this market witnesses the presence of several pharma contract research organizations (CROs) that claim to offer technological support and in vitro ADME services. To date, contract research organization services providers have become a vital part of the pharmaceutical / biopharmaceutical market. Additionally, technological advancements in high-throughput screening methodologies and combinatorial chemistry have made ADME screening easier at early stages in a time-efficient manner. Over the past decade, the ADME toxicology testing industry has undergone substantial consolidation, with various smaller companies being acquired by established and large firms to enhance their services portfolio and wide global reach.
Driven by the growing demand for target-specific drugs and benefits offered by outsourcing in vitro ADME research services, the demand for contract ADME toxicology testing services is anticipated to grow at a steady pace during the forecast period.
The market research report presents an in-depth analysis of the various companies that are engaged in providing ADME toxicology testing services across different segments, as defined in the table below:
| Key Report Attribute | Details | |
| Historical Trend | 2019-2025 | |
| Base Year | 2025 | |
| Forecast Period | 2026-2030 | |
| Market Size 2030 | USD 6.0 billion | |
| Market CAGR | ~3.9% | |
| Type of Services |
|
|
| Type of Assays |
|
|
| Type of Molecules |
|
|
| End Users |
|
|
| Therapeutic Areas |
|
|
| Key Geographical Regions |
|
|
| Key Companies Profiled |
|
|
| PowerPoint Presentation (Complimentary) |
Available | |
| Customization Scope | 15% Free Customization | |
| Excel Data Packs (Complimentary) |
|
|
The key objective of the market report is to provide a detailed market analysis in order to estimate the existing market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunity for in vitro ADME toxicology testing market during the forecast period. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long-term for the historical and forecast period till 2035. In addition, we have segmented the future opportunity across [A] different global regions (North America, Europe, Asia-Pacific, and the rest of the world), [B] types of services (absorption, distribution, metabolism, and excretion), [C] type of assays (across 5+ categories), [D] type of molecule(s) (biologics and small molecules), [E] type of sponsor company (pharmaceutical / biotechnology companies and academic / research institutes) and [F] therapeutic areas (across 10+ categories).
To account for the uncertainties associated with the market and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base, and optimistic tracks of the market's evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market research report are in USD unless otherwise specified.
Based on the type of services, the ADME toxicology testing market is distributed into absorption, distribution, metabolism, and excretion. Currently, metabolism and elimination accounts for the largest share of the market and is poised to hold 60.3% of the overall revenue share by 2030. In the long run, absorption is likely to grow at a higher CAGR of 9.3% during the forecast period till 2030.
Based on the type of molecules, the ADME toxicology testing market is segmented into biologics and small molecules. According to our projection, small molecules are likely to hold a significant share of the market, and the trend is likely to remain unchanged during the forecast period. Driven by the rising demand for small molecules, owing to their ease of administration, there has been a surge in the requirement for ADME toxicology testing services to test absorption, distribution, metabolism and excretion of small molecules which is anticipated to hold 56% of the overall revenue share by 2030. In the long run, ADME toxicology testing services for biologics molecules will grow at a CAGR of 9% during the forecast period.
Based on the end user, the ADME toxicology testing market is distributed amongst pharmaceutical and biotechnology companies and academic research. Driven by the increasing research on innovative drugs, pharmaceutical companies are likely to hold the largest share and are anticipated to account for 67% of overall revenue share by 2030. The academic / research institutes will grow at a faster CAGR of 9.9% till 2030.
Based on the therapeutic areas, the ADME toxicology testing services market is distributed across blood disorders, cardiovascular disorders, gastrointestinal disorders, hormonal disorders, infectious disorders, immunological disorders, and mental and respiratory disorders. Currently, oncology disorders are likely to hold the largest share of the market and are anticipated to hold 42.4% of the overall revenue share by 2030. In the long run, neurological disorders are likely to grow at a CAGR of 6.7% till 2030.
The” In Vitro ADME Toxicology Testing Market: Industry Trends and Global Forecasts, till 2030”, market report features a comprehensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for the CROs providing in vitro ADME toxicology testing services. The market research report presents an in-depth analysis, highlighting the capabilities of various stakeholders across different global regions.
Currently, the market landscape features several industrial and non-industrial players actively offering ADME toxicology testing services. Overall, the market for ADME toxicology testing features the presence of small, mid-sized, large, and very large companies with the required technical expertise to offer ADME toxicology testing services. It is worth noting here that 42% of ADME toxicology testing services providers in this domain are small companies. Large companies are expanding their portfolio and position in this industry by acquiring start-ups / small players. It is worth highlighting here that over 90 companies active in this field are offering ADME toxicology testing services to pharmaceutical companies.
Given the growing incidence of chronic diseases across the globe, pharmaceutical companies experienced a rapid surge in drug development activities. The need for improved therapeutic drugs to target a wide range of diseases has heightened the focus on ADME toxicology testing to ensure the efficiency and safety of medicines for human use. ADME toxicology assay is a useful approach to determining the toxicity and efficiency of drugs—the approach saves plenty of time and costs researchers implement on failed drugs. Further, extensive adoption of ADME toxicology testing by pharmaceutical companies before progressing discovered therapeutic molecules to clinical trials is anticipated to drive the market during the forecast period.
Regulatory agencies, including the US FDA and EMA, have implemented stringent regulatory guidelines on pharmaceutical products to ensure these drugs are safe and effective for treatment. The need to comply with standard drug approval guidelines, several pharmaceutical companies have mandated ADME toxicology testing for the drug evaluation process. The requirement to meet the stringent guidelines of regulatory agencies can act as a driving factor for the ADME toxicology testing market during the forecast period.
One of the significant restraints that may impede the growth of the ADME toxicology testing market is the high cost associated with the installation of equipment and the hiring of skilled personnel. The high cost may create challenges specifically for small and mid-sized pharmaceutical companies, which are likely to prefer outsourcing the service to CROs with necessary capabilities.
The higher expenses associated with ADME toxicology testing equipment and screening methodologies have heightened the interest of pharmaceutical companies in outsourcing testing services from CROs. Notably, mid-sized and large companies prefer to rely on contract service providers that offer a wide range of ADME toxicology testing services such as design, synthesis, initial scale-up, safety pharmacology, and in vitro ADME testing under one roof. The approach of providing a broad range of toxicology testing services under one roof guarantees ease of operation and allows pharmaceutical companies to trust preferred outsourcing partners for receiving services. Furthermore, outsourcing ADME toxicology testing services from reliable partners helps save plenty of time and investment requirements to conduct such operations. Moreover, the complex regulatory compliance for drug approval underscores the requirement of ADME toxicology testing methodologies to ensure drugs are safe. The ongoing requirement of ADME toxicology assay for identifying toxicity at the initial stage of drug discovery offers enormous opportunities for key CRO players in this field to develop advanced platforms to meet the growing demand for testing services.
There has been increased research activity for development of advanced in vitro systems for ADME testing, as the traditionally used 2D cell culture systems have some drawbacks. Additionally, the companies are also pushing the development of such systems so as to replace the animal / in vivo testing. There has been significant investment in development of 3D cell culture assays including organ on chip and organoids in this regard.
On the basis of geographical region, the overall market opportunity is distributed across North America, Europe, Asia-Pacific, and the rest of the world. Based on our projection, North America is dominating the market and is poised to hold 43% of the ADME toxicology testing market share by 2030. It is worth highlighting here that North America has emerged as the hub for the ADME toxicology testing companies, witnessing the presence of several mid-sized and small companies offering CRO services for toxicology testing. Driven by the rising preference for outsourcing ADME toxicology testing services, the Asia-Pacific region is likely to grow at a CAGR of 8.7% during the forecast period.
Examples of key service providers engaged in the ADME toxicology testing industry (which have also been profiled in this market report; the complete list of companies is available in the full report) include:
This market report includes an easily searchable excel database of all the companies providing ADME toxicology testing services worldwide.
Amongst other elements, the market research report includes:
 |
 |
 |
 |
 |
 |
Several recent developments have taken place in the market. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.